ALL AIDSLINE ASK THE DOC CONFERENCES --5th IAS HIV Pathog & Treat --4th IAS HIV Pathog & Treat --3rd IAS HIV Pathog & Treat --2nd IAS HIV Pathog & Treat --1st IAS HIV Pathog & Treat -Intl AIDS Conferences --17th Int Conf AIDS: Toronto (2006) --16th Int Conf AIDS: Toronto (2006) --15th Int Conf AIDS: Bangkok (2004) --14th Int Conf AIDS: Barcelona (2002) --13th Int Conf AIDS: Durban (2000) --12th Int Conf AIDS: Geneva (1998) --11th Int Conf AIDS: Vancouver --10th Int Conf AIDS: Yokohoma --9th Int Conf AIDS: Berlin --8th Int Conf AIDS: Amsterdam --7th Int Conf AIDS: Florence --6th Int Conf AIDS: San Franciso --5th Int Conf AIDS: Montreal --4th Int Conf AIDS: Stockholm --3rd Int Conf AIDS: Washington --2nd Int Conf AIDS: Paris --1st Int Conf AIDS: Atlanta --9th Intl Cong. Drug Therapy: Glasgow 2008 --8th Intl Cong. Drug Therapy: Glasgow 2006 --7th Intl Cong. Drug Therapy: Glasgow 2004 --6th Intl Cong. Drug Therapy: Glasgow 2002 --5th Intl Cong Drug Therapy: Glasgow 2000 --3rd Intl Cong Drug Therapy: Glasgow 1996 --2nd Intl Cong Drug Therapy: Glasgow 1994 --10th Lipo: London, UK --9th Lipo: Sydney, Australia --8th Lipo: San Francisco --7th Lipo: Dublin, Ireland --6th Lipo: Washington, DC --5th Lipo: Paris, France --4th Lipo: San Diego --3rd Lipo: Athens, Greece --2nd Lipo: Toronto, Canada --1st Lipo: San Diego --15th Conf Retroviruses Opportunistic Infect --14th Conf Retroviruses Opportunistic Infect --13th Conf Retroviruses Opportunistic Infect --12th Conf Retroviruses Opportunistic Infect --11th Conf Retroviruses Opportunistic Infect --10th Conf Retroviruses Opportunistic Infect --9th Conf Retroviruses Opportunistic Infect --8th Conf Retroviruses Opportunistic Infect --7th Conf Retroviruses Opportunistic Infect --6th Conf Retroviruses Opportunistic Infect --5th Conf Retroviruses Opportunistic Infect --4th Conf Retroviruses Opportunistic Infect --3rd Conf Retroviruses Opportunistic Infect --2nd Conf Retroviruses Opportunistic Infect --1st Conf Retroviruses Opportunistic Infect --2005 Natl HIV Prev Conf --2003 Natl HIV Prev Conf --1999 Natl HIV Prev Conf --18th Intl Wkshop HIV Drug Resistance --17th Intl Wkshop HIV Drug Resistance --16th Intl Wkshop HIV Drug Resistance --15th Intl Wkshop HIV Drug Resistance --14th Intl Wkshop HIV Drug Resistance --13th Intl Wkshop HIV Drug Resistance --12th Intl Wkshop HIV Drug Resistance --11th Intl Wkshop HIV Drug Resistance --3rd Intl Wkshop HIV Drug Resistance --5th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --4th Intl Wkshop on HIV Drug Resistance & Treatment Strategies --1st Intl Wkshop on HIV Drug Resistance & Treatment Strategies --15th British HIV Ass'n Conf 2009 --14th British HIV Ass'n Conf 2008 --13th British HIV Ass'n Conf 2007 --12th British HIV Ass'n Conf 2006 --11th British HIV Ass'n Conf 2005 --10th British HIV Ass'n Conf 2004 -- 9th British HIV Ass'n Conf 2003 -- 8th British HIV Ass'n Conf 2002 -- 7th British HIV Ass'n Conf 2001 --9th European AIDS Conf. --8th European AIDS Conf. FACT SHEETS --AIDS Treatment Data Network LAW NEWS SERVICES --AIDS Daily Summary --Agence France-Presse --Asia Times --Associated Press --Bay Area Reporter --BBC On-Line --Bangkok Post --Business Wire --CATIE --Chicago Tribune --FDA News --Inter Press Service --Integrated Regional Information Network --Los Angeles Times --Mail & Guardian --Miami Herald --Newsday --New Vision --New York Times --OC Weekly --PRNewswire --Reuters --San Francisco Chronicle --San Francisco Examiner --Sunday Times --UNAIDS --United Press International --Voice of America --Wall Street Journal --Washington Blade PUBLICATIONS --ACRIA --AIDS Treatment News --AIDS Weekly Plus --amfAR --Being Alive --BETA --BMC AIDS Res Therapy --CATIE --Emerging Infectious Diseases --Gay Men's Health Crisis --HIV Education Project --HIV Treatment Bulletin --IAPAC --IAVI --MMWR --Project Inform PLOS --PLOS Biology --PLOS Medicine --PLOS One --PLOS Pathogens --RITA --Treatment Action Group --Women Alive TOPICS Your Search for acute hiv infection and early diseases research program or AIEDRP matched 21 Documents (Page 1 of 1). Results Indexed by relevance.
1.	AEGiS-RITA!: GOVERNMENT RESEARCH: The Acute Infection and Early Disease Research Program - Winter 2002 (99%) Abstract: The Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) sponsors pathogenesis and clinical research of primary (acute) HIV infection through the Acute Infection and Early Disease Research Program (AIEDRP). AIEDRP performs innovative, integrated, investigator-initiated pathogene ... http://www.aegis.org/pubs/rita/2002/ri020108.html File Name: ri020108.html, Size: 13KB, Last Modified: Monday, February 02, 2004 at 11:20:34 PM
2.	AEGiS-08CROI: Community urine testing identified previously unrecognized cases of chronic and early HIV-1 infection. (35%) Abstract: <p><b>BACKGROUND:</b> Maryland has had over 20,000 AIDS cases and reported 2203 new HIV cases in 1999, most of which occurred in Baltimore City (58%). A community coalition for urine HIV testing was developed through Johns Hopkins University to help identify HIV infections and for enrollment into the Acute HIV Infectio ... http://www.aegis.org/conferences/croi/2001/417.html File Name: 417.html, Size: 6KB, Last Modified: Sunday, February 04, 2001 at 8:12:04 PM
3.	AEGiS-15IAC: Dynamics of linear unintegrated and integrated HIV-1 DNA in vitro and in vivo. (17%) Abstract: BACKGROUND: In HIV-1 infected patients HAART can lead to virus suppression ( ... http://www.aegis.org/conferences/iac/2004/thora1400.html File Name: thora1400.html, Size: 6KB, Last Modified: Monday, May 11, 2009 at 10:19:39 PM
4.	[T1-B0104] TREATMENT AND INTERVENTIONS FOR PERSONS IDENTIFIED AS RECENTLY INFECTED (17%) Abstract: Current data indicates CD4 T cell count benefits for 1.5 years or longer associated with limited duration treatment of primary HIV infection, and suggests possible sustained viral load benefits for treatment initiated close to seroconversion. The observational nature of the data limits reliability of conclusions that c ... http://www.aegis.org/conferences/nhivpc/2005/t1-b0104.html File Name: t1-b0104.html, Size: 5KB, Last Modified: Saturday, January 10, 2009 at 12:22:34 AM
5.	[97] INCREASE IN TRANSMITTED NNRTI DRUG RESISTANCE AMONG RECENTLY HIV INFECTED PATIENTS FROM NORTH AMERICA AND AUSTRALIA (17%) Abstract: An increase in the rate of transmitted high-level NNRTI resistance was observed in this cohort. Given that NNRTI resistance does not appear to significantly affect viral fitness, both acquired and transmitted NNRTI resistance will likely be associated with long-term persistence of NNRTI resistance and potential risk of ... http://www.aegis.org/conferences/hivdrw/2006/97.html File Name: 97.html, Size: 8KB, Last Modified: Wednesday, June 14, 2006 at 6:29:23 AM
6.	AEGiS-13CROI [390]: A Comparison of Methods for Estimation of Date of HIV Infection (17%) Abstract: While the specific symptoms apparent during seroconversion may vary, the majority of patients report some typical symptoms. The use of symptom onset date to estimate the date of infection appears to increase accuracy and reduce variation, compared with the midpoint method. Together with laboratory evidence of primary H ... http://www.aegis.org/conferences/croi/2006/390.html File Name: 390.html, Size: 8KB, Last Modified: Sunday, February 05, 2006 at 8:12:04 PM
7.	[WePe8.4B04] GREATER CD4+ T CELL RATE OF GAIN DURING ANTI-RETROVIRAL THERAPY IS ASSOCIATED WITH LOWER PRE-TREATMENT VIRAL POL REPLICATION CAPACITY INDEPENDENT OF VIROLOGIC RESPONSE (17%) Abstract: HIV-1 of lower <i>pol</i> RC predicts greater average rate of CD4+ T cell count increase over the period of observation, independent of virological responses. This may be due to lower T cell activation and sparing of T cell precursors, which have been observed in association with lowered with lowered polRC. ... http://www.aegis.org/conferences/iashivpt/2005/wepe8-4b04.html File Name: wepe8-4b04.html, Size: 10KB, Last Modified: Monday, July 25, 2005 at 6:29:23 AM
8.	[115] SLOW REVERSION OF HIV TRANSMITTED DRUG RESISTANCE TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS IN SEMEN (17%) Abstract: Transmitted drug resistance can persist in the circulating viral population (HIV RNA) in both blood and semen for over three years. The persistence of drug resistant virus in the male genital tract may contribute to the high prevalence rates of transmitted drug resistance. ... http://www.aegis.org/conferences/hivdrw/2005/115.html File Name: 115.html, Size: 6KB, Last Modified: Wednesday, June 08, 2005 at 6:29:23 AM
9.	[165] GAG MUTATIONS IDENTIFIED IN WILD-TYPE HIV-1 THAT IMPACT VIRAL REPLICATION CAPACITY (RC) MAY REPRESENT CYTOTOXIC T-LYMPHOCYTE (CTL) ESCAPE MUTATIONS (17%) Abstract: The observation that <i>gag</i> mutations impact RC in WT viruses was confirmed in a larger dataset, and the many of the same mutations were significant in viruses from patients known to be ART-naïve. Most mutations occurred at known CTL epitopes, suggesting that evasion of host immunity may provide the selective press ... http://www.aegis.org/conferences/hivdrw/2005/165.html File Name: 165.html, Size: 6KB, Last Modified: Wednesday, June 08, 2005 at 6:29:23 AM
10.	[P1] HOST GENETIC DETERMINANTS OF HIV TRANSMISSION AND PATHOGENESIS: SHOULD WE CARE? (17%) Abstract: Possession of a CCL3L1 copy number lower than the population average is associated with markedly enhanced HIV/AIDS susceptibility. This susceptibility is even greater in individuals who also possess diseaseaccelerating CCR5 genotypes. This relationship between CCL3L1 dose and altered HIV/AIDS susceptibility points to a ... http://www.aegis.org/conferences/hivdrw/2005/p1.html File Name: p1.html, Size: 6KB, Last Modified: Wednesday, June 08, 2005 at 6:29:23 AM
11.	AEGiS-12CROI: Outcomes of HAART for Acute/Early HIV-1 Infection after Treatment Discontinuation (17%) Abstract: Subjects who started HAART within 2 weeks of seroconversion had viral load and CD4 count benefits that were statistically significant for 18 months after stopping HAART. In contrast, persons who started HAART between 2 and 26 weeks after seroconversion had a viral load benefit at 6 months that was not sustained at late ... http://www.aegis.org/conferences/croi/2005/568.html File Name: 568.html, Size: 8KB, Last Modified: Tuesday, February 22, 2005 at 8:12:04 PM
12.	AEGiS-12CROI: R5 and X4 Tropic HIV-1 Envelope-mediated Membrane Fusion Is Associated with Disease Stage (17%) Abstract: Patient viruses exhibit broad differences in env-mediated membrane fusion. The envelope gp120 surface protein is a strong determinant of membrane fusion activity. Highly fusogenic viruses, including PBMC-derived viruses, were associated with increased susceptibility to CD4 inhibition. A comparison of plasma derived vir ... http://www.aegis.org/conferences/croi/2005/351.html File Name: 351.html, Size: 8KB, Last Modified: Tuesday, February 22, 2005 at 8:12:04 PM
13.	AEGiS-14IAC: Absence of p31 band identifies persons with recent HIV seroconversion. (17%) Abstract: <p><b>BACKGROUND:</b> Identifying HIV+ persons who are within weeks of HIV antibody seroconversion is important for research and may be important for clinical care, but is often difficult after seroconversion. The p31 band on Western blot (WB) is specific for HIV but has been reported to develop later than the bands ... http://www.aegis.org/conferences/iac/2002/tupec4885.html File Name: tupec4885.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
14.	AEGiS-14IAC: Predicting the HIV set point: comparison of sampling times and methods of set point calculation. (17%) Abstract: <p><b>BACKGROUND:</b> Set point of plasma HIV RNA achieved after primary HIV infection is an important predictor of future disease progression. However, the optimal methods for calculating this set point have not been defined. </p> <p><b>METHODS:</b> Participants in the Baltimore site of the Acute HIV Infection and ... http://www.aegis.org/conferences/iac/2002/b10206.html File Name: b10206.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
15.	AEGiS-14IAC: Rates of toxicity and treatment modification of HAART in patients with primary HIV infection. (17%) Abstract: <p><b>BACKGROUND:</b> Rates of toxicity and treatment modification have been well described in chronically infected patients (pts). However, rates of toxicity and treatment modification have not been adequately described in pts with primary HIV infection (PHI). </p> <p><b>METHODS:</b> Between 1/98 and 1/02, 87 pts w ... http://www.aegis.org/conferences/iac/2002/thpeb7204.html File Name: thpeb7204.html, Size: 7KB, Last Modified: Monday, July 08, 2002 at 6:29:23 AM
16.	AEGiS-9CROI: Predictive Value of Electronic Monitoring of HAART Adherence in Patients with Acute and Early HIV Infection. (17%) Abstract: BACKGROUND: Adherence is a known predictor of treatment outcome with HAART, but has not been evaluated in patients with acute or early HIV infection, where better immune function may affect therapeutic response. METHODS: The predictive value of adherence scores at 2 and 4 months after HAART initiation were assessed wit ... http://www.aegis.org/conferences/croi/2002/544-t.html File Name: 544-t.html, Size: 7KB, Last Modified: Sunday, February 24, 2002 at 8:12:04 PM
17.	AEGiS-08CROI: IL-12 and immune activation in early HIV infection. (17%) Abstract: <p><b>BACKGROUND:</b> Despite considerable literature on the immunology of chronic HIV infection, little is known about immunological events occurring in the very early stages of infection. Production of IL- 12 is impaired in chronic HIV infection. As IL-12 is a cytokine central to the regulation of cellular immunity, ... http://www.aegis.org/conferences/croi/2001/421.html File Name: 421.html, Size: 6KB, Last Modified: Sunday, February 04, 2001 at 8:12:04 PM
18.	[MOAA102] Characterization of human immunodeficiency virus type I in the acute/early phase of infection in the individuals who subsequently become viremia controllers (8%) Abstract: Persons who control HIV viremia after acute infection have reduced viral fitness, linked to Gag-Protease, which is attributable to the complex factors including fitness cost by de novo CTL escape mutations in the recipients, transmission of multiple-class drug resistant strains and transmission of the attenuated escape ... http://www.aegis.org/conferences/iashivpt/2009/moaa102.html File Name: moaa102.html, Size: 10KB, Last Modified: Tuesday, July 21, 2009 at 8:12:04 PM
19.	[ThPE0115] REGIMEN MODIFICATION IN SUBJECTS INITIATING HAART DURING ACUTE OR EARLY HIV INFECTION (8%) Abstract: The most common reason for treatment modification was toxicity. Triple class regimens were modified earlier than either PI or NNRTI based regimens. Toxicity management strategies should be discussed with patients prior to initiating HAART in acute/early infection. ... http://www.aegis.org/conferences/iac/2006/thpe0115.html File Name: thpe0115.html, Size: 9KB, Last Modified: Sunday, August 13, 2006 at 7:00:01 AM
20.	PowerPoint Presentation (3%) Abstract: Early detection of HIV infection in discordant heterosexual couples in Africa Rwanda-Zambia HIV Research Group Susan Allen MD MPH Emory University, Atlanta, GA, USA HIV discordant couples Heterosexual, cohabiting sexual partners One partner HIV+ one partner HIV- Rwanda (N=900) and Zambia (N=1500) fo ... http://www.aegis.org/conferences/iashivpt/2005/mooa0107.ppt File Name: mooa0107.ppt, Size: 2116KB, Last Modified: Monday, July 25, 2005 at 6:29:23 AM
21.	AEGiS-BETA: Open Clinical Trials for HIV/AIDS Treatments - Winter, 2001 (1%) Abstract: Important note: Information in this article was accurate in January 2001. The state of the art may have changed since the publication date.Open Clinical Trials for HIV/AIDS Treatments Bulletin of Experimental Treatments for AIDS, Winter 2001 Christopher GortnerThe following listings were gathered from a variet ... http://www.aegis.org/pubs/beta/2001/be010112.html File Name: be010112.html, Size: 33KB, Last Modified: Wednesday, September 18, 2002 at 6:20:43 PM
	1
	AEGiS Search Engine. Status: The Index is up to date.